LGND

Ligand Pharmaceuticals Inc

$312.37

2.01 (0.65%) Today

— up— down

Compare LGND

Market Cap

$6.19B+76.3%

Revenue (TTM)

$266.63M+54.9%

Net Income (TTM)

$188.42M

EPS (TTM)

9.40

Shares Out

20.04M

P/E Ratio

32.05

Forward P/E

26.65

Open

$310.52

Previous Close

$310.36

Day Range

$306.95 – $316.94

52-Week Range

$175.56 – $326.63

Beta

1.22

Volume

500.75K

Avg Volume

317.82K

Analyst Rating

Buy

Exchange

NASDAQ NMS - GLOBAL MARKET

About LGND

Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma (cancer) treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.